Which statement about immunosuppressive therapy is true for balancing risk?

• A. Higher immunosuppression reduces infection risk.
• B. Adequate immunosuppression lowers rejection risk but increases infection risk; drug levels must be monitored.
• C. Immunosuppressants do not affect infection risk.
• D. You should always stop immunosuppressants if infection occurs.

Answer: (B)

Balancing infection risk with rejection risk hinges on keeping immunosuppression at a level that prevents organ rejection while avoiding excessive suppression that leaves the patient vulnerable to infections. This requires careful monitoring and adjustment of drug levels to fit the individual patient.

This statement is best because it directly acknowledges the trade-off: adequate immunosuppression lowers the chance of rejection, but it raises the risk of infection, and the way to manage this is by closely monitoring drug levels to stay within a therapeutic range. Drug-level monitoring helps tailor therapy to the person’s metabolism, interactions with other medications, kidney function, and the presence of illness, all of which can shift the balance.

In real-world practice, immunosuppressants are chosen and dosed to achieve enough suppression to protect the transplanted organ without tipping into over-suppression. If an infection occurs or a patient’s condition changes, clinicians may adjust the regimen rather than abruptly stopping therapy, since stopping immunosuppression can precipitate rejection and destabilize graft function. Some drugs may be reduced or temporarily held depending on the infection, but the overarching goal remains maintaining an appropriate balance through careful monitoring.

Unlike the other statements, this choice captures both the risk–benefit trade-off and the role of drug-level monitoring in optimizing therapy.